Biotech Companies are Increasingly Focused on Deadly Diseases With Significant Unmet Need

According to a story from finanznachrichten.de, biotechnology companies are starting to set their sights on treating deadly diseases that are lacking effective treatment options, including some diseases that are considered…

Continue Reading Biotech Companies are Increasingly Focused on Deadly Diseases With Significant Unmet Need

Study Shows Distal Renal Tubular Acidosis Patient Outcomes Vary Across Country Lines

What is Distal Renal Tubular Acidosis? Distal renal tubular acidosis (dRTA) is a rare condition which affects approximately 1 in every 100,000 people worldwide. It is caused by a build up…

Continue Reading Study Shows Distal Renal Tubular Acidosis Patient Outcomes Vary Across Country Lines

Study Shows Treatment may be Effective for Chronic Kidney Disease but Increase Risk of Hyperkalemia

A recent study, called TOPCAT, evaluated the effects of spironolactone as a treatment for individuals living with Chronic Kidney Disease (CKD) who are also diagnosed with heart failure with preserved ejection fraction,…

Continue Reading Study Shows Treatment may be Effective for Chronic Kidney Disease but Increase Risk of Hyperkalemia
Computer Simulation Shows Surgery is Overprescribed for Kidney Cancer Patients
source: pixabay.com

Computer Simulation Shows Surgery is Overprescribed for Kidney Cancer Patients

The most common treatment for someone who is discovered to have early stage kidney cancer is surgery. The patient's tumors and a part of their kidneys are removed through a…

Continue Reading Computer Simulation Shows Surgery is Overprescribed for Kidney Cancer Patients

Dosing Begins in Phase 3 IgA Nephropathy Clinical Trial

According to a story from BioSpace, the biopharmaceutical company Retrophin, Inc., recently announced that the first patient has been treated in the company's Phase 3 clinical trial testing sparsentan as…

Continue Reading Dosing Begins in Phase 3 IgA Nephropathy Clinical Trial

Drug for Treating Autosomal Dominant Polycystic Kidney Disease Gets Expanded Indication

According to a story from businesswire.com, Otsuka Pharmaceutical Europe Ltd recently announced that its product JINARC, also known as tolvaptan, now has an expanded therapeutic indication after a recent approval…

Continue Reading Drug for Treating Autosomal Dominant Polycystic Kidney Disease Gets Expanded Indication

Results From Studies of an Experimental Drug for Chronic Kidney Disease Have Been Announced

Results from two studies looking at the effects of an experimental drug (bardoxolone) on kidney function in patients with chronic kidney disease (CKD) have been released. One of the studies…

Continue Reading Results From Studies of an Experimental Drug for Chronic Kidney Disease Have Been Announced